Principal Securities’s SpringWorks Therapeutics SWTX Stock Holding History

Principal Securities’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8	Closed	-$376	–	3839
2025 Q2	$376	Sell	8 -125	-94%	-$5.56K	﹤0.01%	3528
2025 Q1	$4.8K	Hold	133	–	–	﹤0.01%	2787
2024 Q4	$4.8K	Buy	133 +29	+28%	+$1.01K	﹤0.01%	2784
2024 Q3	$3.33K	Buy	104 +55	+112%	+$2.06K	﹤0.01%	2810
2024 Q2	$1.85K	Buy	49 +16	+48%	+$673	﹤0.01%	2934
2024 Q1	$1.62K	Buy	33 +1	+3%	+$46	﹤0.01%	2929
2023 Q4	$1.17K	Buy	+32	New	+$835	﹤0.01%	2919

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Principal Securities's SWTX Position: Q3 2025 in Review

Principal Securities sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 8 shares — an estimated $376 sold.

Principal Securities first reported a position in SWTX in Q4 2023 and held it in 7 quarters. The position peaked at $4.8K in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Principal Securities reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Principal Securities sold 8 SpringWorks Therapeutics shares in Q3 2025, an estimated $376.
Principal Securities first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 7 quarters.
Principal Securities's SpringWorks Therapeutics position peaked at $4.8K in Q1 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Principal Securities's 13F filing for Q3 2025, filed 12 Nov 2025.